Almirall SA (GB:0O9B)
LSE:0O9B
0O9B Stock Chart & Stats
€12.90
-€0.04(-0.52%)
At close: 4:00 PM EST
€12.90
-€0.04(-0.52%)
Day’s Range― - ―
52-Week Range€8.74 - €13.98
Previous CloseN/A
Volume457.00
Average Volume (3M)2.60K
Market Cap
€2.59B
Enterprise Value€2.60B
Total Cash (Recent Filing)€338.82M
Total Debt (Recent Filing)€342.86M
Price to Earnings (P/E)35.1
Beta0.97
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding214,785,200
10 Day Avg. Volume4,186
30 Day Avg. Volume2,602
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.07Price Target Upside9.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.44
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Recovering Revenue & ProfitabilityAlmirall’s return to positive operating and net margins alongside 2025 revenue growth signals an operational inflection. Sustained profitability supports reinvestment in dermatology R&D and commercialization, improving ability to fund growth without relying solely on external financing.
Manageable Leverage And Solid Capital BaseLower leverage and a stable equity base provide financial flexibility to pursue partnerships, M&A, or incremental R&D spend. A conservative balance sheet reduces refinancing risk and supports investment through industry cycles, enhancing long-term resilience.
Rebound In Operating Cash Flow And FCFThe sharp FCF rebound in 2025 demonstrates improved cash conversion and internal funding capacity. Reliable cash generation supports commercial expansion and pipeline funding, lowering dependence on dilutive financing and enabling sustainable capital allocation if the trend persists.
Bears Say
Historic Earnings & Cash Flow VolatilityPast swings between losses and profits and episodic negative FCF indicate operating and execution risk. This volatility complicates long-term planning, raises the probability of future financing needs, and weakens confidence in sustainably funding R&D or commercial scale-up.
Low Returns On CapitalA low ROE implies limited capital efficiency versus peers, constraining ability to generate shareholder value from invested equity. Persistently low returns reduce scope for attractive dividends or buybacks and raise questions about long-term allocation effectiveness.
Uneven Profitability And Thin Margins HistoricallyHistoric thin net margins and intermittent profitability suggest structural pressure on pricing or cost base in core dermatology markets. If margins remain constrained, long-term free cash generation and ability to fund innovation or absorb competitive shocks will be limited.
Almirall News
0O9B FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest share price was €8.74 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.59B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is May 11, 2026 which is in 33 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Feb 23, 2026. The company reported €0.091 earnings per share for the quarter, missing the consensus estimate of €0.16 by -€0.069.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Undervalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Almirall SA have?
Almirall SA has 214,785,200 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.091 in its last earnings report, missing expectations of €0.16. Following the earnings report the stock price went down -5.821%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in GB:0O9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€14.07 (9.04% Upside)
€14.07 (9.04% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.06%
12-Months-Change
Fundamentals
Return on Equity
3.96%
Trailing 12-Months
Asset Growth
-2.48%
Trailing 12-Months
Company Description
Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
0O9B Stock 12 Month Forecast
Average Price Target
€14.07
▲(9.04% Upside)
Technical Analysis
Options Prices
Currently, No data available
---